() RCT II 75 at Aim: to examine the effect of vitamin D Mean (95% CI) VDA at age 2 wk was: Low risk of 2 wk supplementation during pregnancy on bias; see 52 IU/L (12, 217 IU/L) in the placebo vitamin D activity (VDA) in the first 2 mo of Section 2.7 44 at 2 group, lactation wk and 51 IU/L (17, 151 IU/L) in the 1000-IU group, 2 mth Setting: Auckland, New Zealand and Population: Women who were enrolled in a 74 IU/L (25, 221 IU/L) in the 2000-IU group. randomized, double-blinded, Mean (95% CI) VDA at 2 mo was: trial of vitamin D supplementation 45 IU/L (16, 124 IU/L), 43 IU/L (18, 103 IU/L), during pregnancy. and 58 IU/L (15, 224 IU/L), respectively. Intervention: Pregnant women were enrolled at There was no significant interaction in VDA 27 wk of gestation and randomly assigned to the between the sample-collection time and following 3 groups: placebo, one dosage of daily treatment (P=0.61), but there was a oral vitamin D3 (1000 IU), or 2 dosages of daily difference between lower- and oral vitamin D3 (2000 IU). treatment groups (P = 0.04). Outcomes: Serum 25(OH)D was measured at enrollment, at 36 wk of gestation, and in cord blood at birth. Study participants who were breastfeeding were invited to provide breast-milk samples for VDA measurement [concentration of vitamin D2, vitamin D3, 25(OH)D2, and 25(OH)D3] at 2 wk and 2 mo postpartum.
() RCT II 75 at 2 wk 44 at 2 wk and 2 mth Aim: to examine the effect of vitamin D supplementation during pregnancy on vitamin D activity (VDA) in the first 2 mo of lactation Setting: Auckland, New Zealand Population: Women who were enrolled in a randomized, double-blinded, trial of vitamin D supplementation during pregnancy. Intervention: Pregnant women were enrolled at 27 wk of gestation and randomly assigned to the following 3 groups: placebo, one dosage of daily oral vitamin D3 (1000 IU), or 2 dosages of daily oral vitamin D3 (2000 IU). Outcomes: Serum 25(OH)D was measured at enrollment, at 36 wk of gestation, and in cord blood at birth. Study participants who were breastfeeding were invited to provide breast-milk samples for VDA measurement [concentration of vitamin D2, vitamin D3, 25(OH)D2, and 25(OH)D3] at 2 wk and 2 mo postpartum. Mean (95% CI) VDA at age 2 wk was: 52 IU/L (12, 217 IU/L) in the placebo group, 51 IU/L (17, 151 IU/L) in the 1000-IU group, and 74 IU/L (25, 221 IU/L) in the 2000-IU group. Mean (95% CI) VDA at 2 mo was: 45 IU/L (16, 124 IU/L), 43 IU/L (18, 103 IU/L), and 58 IU/L (15, 224 IU/L), respectively. There was no significant interaction in VDA between the sample-collection time and treatment (P=0.61), but there was a difference between lower- and treatment groups (P = 0.04). Low risk of bias; see Section 2.7
Vitamin%20D%20evidence%20evaluation%2022May17.docx